Enhanced AkaLuc Bioluminescence Imaging for Longitudinal Intravital Monitoring of Minimal Residual Disease in a Murine Model of Triple-negative Breast Cancer

Guardado en:
Detalles Bibliográficos
Publicado en:bioRxiv (Jan 22, 2025)
Autor principal: Steinbauer, Silvia
Otros Autores: Cowles, Jamie Daniel, Mohammad Ali Sabbaghi, Marle Poppelaars, Hussain, Azaz, Wagesreither, Marina, Laimer-Gruber, Daniela, Tovari, Jozsef, Szakacs, Gergely, Csiszar, Agnes
Publicado:
Cold Spring Harbor Laboratory Press
Materias:
Acceso en línea:Citation/Abstract
Full Text - PDF
Full text outside of ProQuest
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

MARC

LEADER 00000nab a2200000uu 4500
001 3158241614
003 UK-CbPIL
022 |a 2692-8205 
024 7 |a 10.1101/2025.01.18.633734  |2 doi 
035 |a 3158241614 
045 0 |b d20250122 
100 1 |a Steinbauer, Silvia 
245 1 |a Enhanced AkaLuc Bioluminescence Imaging for Longitudinal Intravital Monitoring of Minimal Residual Disease in a Murine Model of Triple-negative Breast Cancer 
260 |b Cold Spring Harbor Laboratory Press  |c Jan 22, 2025 
513 |a Working Paper 
520 3 |a Triple-negative breast cancer (TNBC) is an aggressive form of cancer with poor prognosis. Beyond the absence of targeted therapies, a major challenge is its high recurrence rate, driven by the outgrowth of residual tumor cells that survive chemotherapy and persist during minimal residual disease (MRD). To monitor the therapy response of TNBC by enhanced intravital imaging, we established a clinically relevant combination chemotherapy protocol for the treatment of mouse mammary tumors engrafted from K14cre;Brca1F/F;Trp53F/F (KB1P) organoids engineered to express an mCherry-AkaLuc dual reporter (mCA-KB1P). Reproducible MRD and relapse response patterns with significantly extended relapse-free survivals were achieved with the TAC protocol, consisting of docetaxel, doxorubicin and cyclophosphamide. AkaLuc bioluminescence imaging (AkaBLI) of mCA-KB1P organoids verified the single-cell sensitivity of the system in vitro, and showed a detection limit of approximately 1000 cells in the mammary gland of living mice. Unexpectedly, mCA-KB1P organoids elicited an immune response, which necessitated the use of immunodeficient hosts for the longitudinal intravital monitoring of MRD. AkaBLI and an adapted TAC protocol enabled, for the first time, the non-invasive intravital tracking and an estimation of the number of surviving tumor cells in the MRD state following intensive chemotherapy. Engineering KB1P organoids for Histon2B-mCherry reporter expression (HmC-KB1P) enabled the estimation of tumor cell survival also in syngeneic immunocompetent hosts. Flow cytometry and histological analysis revealed that immunocompetent hosts harbored only a few residual cells at MRD, which exhibited a transient loss of epithelial characteristics, whereas immunodeficient hosts had a greater number of surviving cells with a maintained epithelial phenotype. These findings are consistent with a role of the immune system in shaping phenotypic changes influencing survival following chemotherapy. Together, the results demonstrate the utility of the AkaBLI system for rare tumor cell tracking and highlight the role of the immune system in triggering adaptive responses to chemotherapy.Competing Interest StatementThe authors have declared no competing interest. 
653 |a Organoids 
653 |a Mammary gland 
653 |a Immunocompetence 
653 |a Minimal residual disease 
653 |a Tumor cells 
653 |a Medical prognosis 
653 |a Immunodeficiency 
653 |a Cyclophosphamide 
653 |a Cancer therapies 
653 |a Immune system 
653 |a Phenotypes 
653 |a Doxorubicin 
653 |a Breast cancer 
653 |a Flow cytometry 
653 |a Chemotherapy 
653 |a Animal models 
653 |a Cell survival 
653 |a Bioluminescence 
653 |a Immune response 
700 1 |a Cowles, Jamie Daniel 
700 1 |a Mohammad Ali Sabbaghi 
700 1 |a Marle Poppelaars 
700 1 |a Hussain, Azaz 
700 1 |a Wagesreither, Marina 
700 1 |a Laimer-Gruber, Daniela 
700 1 |a Tovari, Jozsef 
700 1 |a Szakacs, Gergely 
700 1 |a Csiszar, Agnes 
773 0 |t bioRxiv  |g (Jan 22, 2025) 
786 0 |d ProQuest  |t Biological Science Database 
856 4 1 |3 Citation/Abstract  |u https://www.proquest.com/docview/3158241614/abstract/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch 
856 4 0 |3 Full Text - PDF  |u https://www.proquest.com/docview/3158241614/fulltextPDF/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch 
856 4 0 |3 Full text outside of ProQuest  |u https://www.biorxiv.org/content/10.1101/2025.01.18.633734v1